As of July 24, 2026, Cullinan Therapeutics's top three insider holders are Capital Management Lp Lynx1 (TenPercentOwner, 8.96Mn shares), Capital Management Lp Lynx1 (TenPercentOwner, 8.80Mn shares), Capital Management Lp Lynx1 (TenPercentOwner, 8.56Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Partners L P/Il Bvf | - | 64,161 | 0 | 19 Jan, 2023 |
| Ansbert Gadicke | - | 244,551 | 7,648,268 | 20 Sep, 2021 |
| Thomas Ebeling | - | 186,653 | 0 | 11 Jun, 2024 |
| Patrick Baeuerle | Chief Scientific Officer | 76,000 | 0 | 21 Feb, 2023 |
| Mary Kay Fenton | Chief Financial Officer | 126,380 | 0 | 23 Feb, 2026 |
| Raymond T Keane | Chief Legal Officer | 24,124 | 0 | 15 Feb, 2022 |
| Morana Jovan-Embiricos | - | 207,803 | 0 | 28 Jun, 2022 |
| Oncology Impact Fund L.P. Ubs | - | 7,805,483 | 0 | 25 Aug, 2021 |
| Nadim Ahmed | President And Ceo | 390,803 | 0 | 25 Feb, 2026 |
| Leigh Zawel | - | 69,785 | 0 | 15 Feb, 2022 |
| Corrine Savill | Chief Business Officer | 240,990 | 0 | 21 Feb, 2025 |
| Jennifer Michaelson | Chief Scientific Officer | 170,844 | 0 | 09 Mar, 2026 |
| Vision Scs F2 | - | 1,255,963 | 0 | 04 Aug, 2022 |
| Bioscience I 2017 Ltd F2 | - | 537,392 | 0 | 23 Jun, 2022 |
| Jeffrey Trigilio | Chief Financial Officer | 133,919 | 0 | 23 Feb, 2024 |
| Jacquelyn L Sumer | Chief Legal Officer | 128,089 | 0 | 25 Feb, 2026 |
| Capital Management Lp Lynx1 | - | 0 | 8,963,500 | 30 Oct, 2025 |
| Jeffrey Alan Jones | Chief Medical Officer | 159,968 | 0 | 25 Feb, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | A | 4,000 | $4.30 | 178,844 | D | M |
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | A | 4,000 | $4.30 | 178,844 | D | M |
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | A | 4,000 | $4.30 | 178,844 | D | M |
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | D | 8,000 | $15.68 | 170,844 | D | S |
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | D | 8,000 | $15.68 | 170,844 | D | S |
| 05 Mar, 2026 | Jennifer Michaelson | Common Stock | D | 8,000 | $15.68 | 170,844 | D | S |
| 05 Mar, 2026 | Jennifer Michaelson | Stock Option (Right to Buy) | D | 4,000 | $0.00 | 120,987 | D | M |
| 05 Mar, 2026 | Jennifer Michaelson | Stock Option (Right to Buy) | D | 4,000 | $0.00 | 120,987 | D | M |
| 05 Mar, 2026 | Jennifer Michaelson | Stock Option (Right to Buy) | D | 4,000 | $0.00 | 120,987 | D | M |
| 25 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,780 | $14.14 | 174,844 | D | S |
| 25 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,780 | $14.14 | 174,844 | D | S |
| 25 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,780 | $14.14 | 174,844 | D | S |
| 24 Feb, 2026 | Jacquelyn L Sumer | Common Stock | D | 3,601 | $14.47 | 128,089 | D | S |
| 24 Feb, 2026 | Jeffrey Alan Jones | Common Stock | D | 4,582 | $14.47 | 159,968 | D | S |
| 23 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,752 | $13.99 | 180,225 | D | S |
| 23 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,752 | $13.99 | 180,225 | D | S |
| 24 Feb, 2026 | Jacquelyn L Sumer | Common Stock | D | 3,601 | $14.47 | 128,089 | D | S |
| 24 Feb, 2026 | Jeffrey Alan Jones | Common Stock | D | 4,582 | $14.47 | 159,968 | D | S |
| 24 Feb, 2026 | Nadim Ahmed | Common Stock | D | 13,515 | $14.47 | 390,803 | D | S |
| 23 Feb, 2026 | Jennifer Michaelson | Common Stock | D | 1,752 | $13.99 | 180,225 | D | S |